Date: 2012-01-23
Type of information: Fundraising
Company: Eyevensys (France)
Investors: InnoBio (France) - nserm Transfert Initiative (France)
Amount: €1.6 million
Funding type: capital increase
Planned used:
- Created in December 2008, Eyevensys is developing a new original method for non-viral gene therapy for prolonged production of any therapeutic protein to treat eye diseases. This single-use electrotransfer device will first be used for the first-line treatment of an orphan eye disease, uveitis. In a second step, the company intends to expand the application of the device into more common eye diseases, as diabetic retinopathy and age-related macular degeneration. This fundraising will enable Eyevensys to further advance the preclinical development of the device.
Others:
- The french biotech fund, InnoBio and Inserm Transfert Initiative have agreed to participate in the capital increase of Eyevensys. Innobio will provide €0.65 million and Inserm Transfert Initiative €0.3 million. This financing is part of a total fundraising of € 1.6 million euros that will allow Eyevensys to expand its medical device in ophthalmology.
Therapeutic area: Ophtalmological diseases
Is general: Yes
